Terms: = Lymphoma AND SRSF2, Q01130, 6427, SFRS2 AND Treatment
10 results:
1. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract] [Full Text] [Related]
2. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Sanber K; Ye K; Tsai HL; Newman M; Webster JA; Gojo I; Ghiaur G; Prince GT; Gondek LP; Smith BD; Levis MJ; DeZern AE; Ambinder AJ; Dalton WB; Jain T
Leuk Lymphoma; 2023 Apr; 64(4):846-855. PubMed ID: 36744656
[TBL] [Abstract] [Full Text] [Related]
3. Aberrant RNA splicing and therapeutic opportunities in cancers.
Yamauchi H; Nishimura K; Yoshimi A
Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
[TBL] [Abstract] [Full Text] [Related]
4. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
Zhou N; Xu X; Liu Y; Wang Y; Wei W
Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
[TBL] [Abstract] [Full Text] [Related]
5. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
Castillo-Tokumori F; Talati C; Al Ali N; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e956-e960. PubMed ID: 32778513
[TBL] [Abstract] [Full Text] [Related]
6. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
Wang YW; Tsai CH; Lin CC; Tien FM; Chen YW; Lin HY; Yao M; Lin YC; Lin CT; Cheng CL; Tang JL; Chou WC; Hou HA; Tien HF
Ann Hematol; 2020 Mar; 99(3):501-511. PubMed ID: 31965269
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis.
Lee YC; Hsieh CC; Lee YL; Li CY
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):558-568. PubMed ID: 29970342
[TBL] [Abstract] [Full Text] [Related]
8. MALAT1 in Human Adipose Stem Cells Modulates Survival and Alternative Splicing of PKCδII in HT22 Cells.
El Bassit G; Patel RS; Carter G; Shibu V; Patel AA; Song S; Murr M; Cooper DR; Bickford PC; Patel NA
Endocrinology; 2017 Jan; 158(1):183-195. PubMed ID: 27841943
[TBL] [Abstract] [Full Text] [Related]
9. Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.
Saillard C; Guermouche H; Derrieux C; Bruneau J; Frenzel L; Couronne L; Asnafi V; Macintyre E; Trinquand A; Lhermitte L; Molina T; Suarez F; Lemonnier F; Kosmider O; Delarue R; Hermine O; Cheminant M
Hematol Oncol; 2017 Dec; 35(4):864-868. PubMed ID: 27353473
[TBL] [Abstract] [Full Text] [Related]
10. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract] [Full Text] [Related]
